Robertson Stephens Wealth Management LLC lowered its position in AstraZeneca PLC (NYSE:AZN) by 13.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,499 shares of the company’s stock after selling 697 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in AstraZeneca were worth $246,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Optimum Investment Advisors increased its stake in shares of AstraZeneca by 20.0% during the 3rd quarter. Optimum Investment Advisors now owns 1,200 shares of the company’s stock worth $66,000 after purchasing an additional 200 shares during the last quarter. Cordasco Financial Network increased its position in AstraZeneca by 3.0% during the 3rd quarter. Cordasco Financial Network now owns 6,868 shares of the company’s stock valued at $376,000 after purchasing an additional 200 shares during the period. Usca Ria LLC lifted its position in shares of AstraZeneca by 3.7% in the 3rd quarter. Usca Ria LLC now owns 5,617 shares of the company’s stock worth $308,000 after purchasing an additional 200 shares during the period. Berman Capital Advisors LLC increased its holdings in AstraZeneca by 11.9% during the third quarter. Berman Capital Advisors LLC now owns 1,887 shares of the company’s stock valued at $102,000 after buying an additional 201 shares during the period. Finally, Sage Rhino Capital LLC grew its stake in AstraZeneca by 2.1% in the second quarter. Sage Rhino Capital LLC now owns 9,851 shares of the company’s stock valued at $521,000 after purchasing an additional 207 shares during the last quarter. Institutional investors and hedge funds own 16.30% of the company’s stock.
Shares of AstraZeneca stock opened at $55.30 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 1.14. The company has a fifty day simple moving average of $53.79 and a 200-day simple moving average of $54.48. The stock has a market cap of $145.14 billion, a price-to-earnings ratio of 66.63, a PEG ratio of 1.63 and a beta of 0.50. AstraZeneca PLC has a 12-month low of $36.15 and a 12-month high of $64.94.
AstraZeneca (NYSE:AZN) last posted its earnings results on Tuesday, November 10th. The company reported $0.47 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.03. The business had revenue of $6.58 billion for the quarter, compared to analysts’ expectations of $6.65 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The business’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.99 earnings per share. On average, analysts forecast that AstraZeneca PLC will post 2.03 earnings per share for the current fiscal year.
AZN has been the topic of several recent analyst reports. Berenberg Bank started coverage on shares of AstraZeneca in a report on Tuesday, September 29th. They set a “buy” rating on the stock. HSBC upgraded AstraZeneca from a “reduce” rating to a “hold” rating in a research note on Wednesday, November 11th. Oddo Bhf upgraded AstraZeneca from a “reduce” rating to a “buy” rating in a report on Wednesday, September 23rd. Zacks Investment Research cut shares of AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 target price on the stock. in a research note on Wednesday, July 29th. Finally, Barclays restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, July 29th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and an average target price of $61.00.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.
Recommended Story: What is the price-to-earnings growth (PEG) ratio?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.